Atara Biotherapeutics (ATRA) Competitors $15.85 +0.22 (+1.41%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$16.11 +0.26 (+1.67%) As of 10/8/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ATRA vs. ORIC, KMDA, AURA, KRRO, DSGN, DRUG, ANNX, LXEO, BNTC, and DMACShould you be buying Atara Biotherapeutics stock or one of its competitors? The main competitors of Atara Biotherapeutics include Oric Pharmaceuticals (ORIC), Kamada (KMDA), Aura Biosciences (AURA), Korro Bio (KRRO), Design Therapeutics (DSGN), Bright Minds Biosciences (DRUG), Annexon (ANNX), Lexeo Therapeutics (LXEO), Benitec Biopharma (BNTC), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. Atara Biotherapeutics vs. Its Competitors Oric Pharmaceuticals Kamada Aura Biosciences Korro Bio Design Therapeutics Bright Minds Biosciences Annexon Lexeo Therapeutics Benitec Biopharma DiaMedica Therapeutics Oric Pharmaceuticals (NASDAQ:ORIC) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment. Which has preferable valuation & earnings, ORIC or ATRA? Atara Biotherapeutics has higher revenue and earnings than Oric Pharmaceuticals. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOric PharmaceuticalsN/AN/A-$127.85M-$1.89-7.56Atara Biotherapeutics$128.94M0.86-$85.40M-$0.43-36.86 Do analysts prefer ORIC or ATRA? Oric Pharmaceuticals currently has a consensus price target of $17.29, suggesting a potential upside of 21.05%. Atara Biotherapeutics has a consensus price target of $21.00, suggesting a potential upside of 32.49%. Given Atara Biotherapeutics' higher probable upside, analysts clearly believe Atara Biotherapeutics is more favorable than Oric Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oric Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70Atara Biotherapeutics 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50 Is ORIC or ATRA more profitable? Atara Biotherapeutics has a net margin of 3.07% compared to Oric Pharmaceuticals' net margin of 0.00%. Atara Biotherapeutics' return on equity of -8.34% beat Oric Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Oric PharmaceuticalsN/A -51.75% -47.09% Atara Biotherapeutics 3.07%-8.34%6.61% Which has more volatility and risk, ORIC or ATRA? Oric Pharmaceuticals has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Do institutionals and insiders hold more shares of ORIC or ATRA? 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 6.8% of Oric Pharmaceuticals shares are owned by insiders. Comparatively, 4.0% of Atara Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media prefer ORIC or ATRA? In the previous week, Oric Pharmaceuticals had 7 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 10 mentions for Oric Pharmaceuticals and 3 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.51 beat Oric Pharmaceuticals' score of 0.10 indicating that Atara Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Atara Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAtara Biotherapeutics beats Oric Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATRA vs. The Competition Export to ExcelMetricAtara BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$109.77M$3.35B$6.09B$10.54BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-36.8621.5785.3527.60Price / Sales0.86271.49539.78202.41Price / CashN/A47.1237.9261.55Price / Book-0.9410.1413.016.76Net Income-$85.40M-$52.31M$3.30B$275.88M7 Day Performance9.46%5.14%4.34%2.81%1 Month Performance32.75%14.68%9.49%9.24%1 Year Performance102.94%30.98%84.83%35.42% Atara Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATRAAtara Biotherapeutics4.6236 of 5 stars$15.85+1.4%$21.00+32.5%+102.2%$109.77M$128.94M-36.86330News CoverageAnalyst ForecastORICOric Pharmaceuticals4.1601 of 5 stars$11.62+4.5%$17.29+48.8%+50.5%$1.08BN/A-6.1580News CoverageAnalyst ForecastInsider TradeKMDAKamada4.5351 of 5 stars$6.87+3.0%$13.00+89.2%+30.0%$383.56M$160.95M20.21360Positive NewsAnalyst ForecastAnalyst RevisionAURAAura Biosciences2.2095 of 5 stars$6.17+0.2%$22.00+256.6%-27.9%$382.66MN/A-3.1550News CoverageAnalyst ForecastKRROKorro Bio2.18 of 5 stars$42.80+5.3%$86.83+102.9%+30.8%$381.83M$2.27M-4.3970News CoveragePositive NewsDSGNDesign Therapeutics0.0487 of 5 stars$6.85+4.3%N/A+41.1%$374.15MN/A-6.1240News CoverageAnalyst ForecastDRUGBright Minds Biosciences3.0523 of 5 stars$57.45+9.0%$81.00+41.0%+5,011.1%$371.36MN/A-61.77N/AANNXAnnexon2.957 of 5 stars$3.12-7.4%$12.50+300.6%-54.3%$370.32MN/A-2.4260Positive NewsAnalyst ForecastHigh Trading VolumeLXEOLexeo Therapeutics3.0546 of 5 stars$6.66-1.6%$15.33+130.2%-8.2%$365.59M$650K-2.0458Trending NewsAnalyst ForecastBNTCBenitec Biopharma2.0147 of 5 stars$13.99+2.1%$24.80+77.3%+49.0%$359.63M$80K-9.5220News CoverageAnalyst DowngradeDMACDiaMedica Therapeutics2.3507 of 5 stars$6.91-0.4%$12.33+78.5%+49.7%$358.72MN/A-10.0120Analyst Forecast Related Companies and Tools Related Companies ORIC Alternatives KMDA Alternatives AURA Alternatives KRRO Alternatives DSGN Alternatives DRUG Alternatives ANNX Alternatives LXEO Alternatives BNTC Alternatives DMAC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATRA) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
